<div id="readability-page-1"><div><p>(MT Newswires) -- China's medical products administrator granted Beijing Foyou Pharma (SHA:601089) a drug registration certificate for its candesartan cilexetil and hydrochlorothiazide tablets for hypertension, according to a Tuesday filing with the Shanghai bourse.</p><p> The original manufacturer's candesartan cilexetil-hydrochlorothiazide tablets are not available in China. Takeda and AstraZeneca jointly developed the drug, the filing said.</p><p> The drug is indicated for patients with blood pressures not effectively controlled by just candesartan cilexetil or hydrochlorothiazide alone, among others.</p><p>Shares closed 2% higher on Tuesday.</p></div></div>

福元医药

<p>（MT Newswires）-- 根据周二在上海证券交易所的文件，中国医疗产品管理局已向北京福元医药（SHA:601089）颁发了其用于治疗高血压的氯沙坦西酯和氢氯噻嗪片的药品注册证书。原制造商的氯沙坦西酯 - 氢氯噻嗪片在中国并不可用。文件指出，该药物由武田制药和阿斯利康共同开发。该药物适用于仅用氯沙坦西酯或氢氯噻嗪单独治疗效果不佳的高血压患者等。周二股价上涨了 2%</p>

福元医药获得中国高血压药片的药品注册许可